2 results
Approved WMORecruiting
Assessment of safety and clinical performance of the DREAMS 3G in de novo coronary artery lesion in order to achieve and to obtain CE-approval
Approved WMORecruiting
The purpose of this Phase II/III study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in combination with risdiplam (…